Pharma group MSD has joined forces with Owkin to develop ... to be lower ,so is not tested for routinely. The hope is that AI can be harnessed to identify patients quickly with MSI-H who could ...

MSD's head of R&D, Dean Li, said that the licensing deal will "build on our experience targeting incretin biology to evaluate HS-10535 and its potential to provide additional cardiometabolic ...

First, Li said policy must be based on “science, not science fiction.” In other words, policymakers should focus on the current reality of AI, not on grandiose futuristic scenarios, “whether ...

Credit: Heindri Conradie (MSD), associate minister of social development Penny Simmonds, Matt Owen (pAI2), Vanessa Sorenson (Microsoft NZ), Chris Denly (MSD), Amanda Nicolle (MSD). Microsoft, the ...